What is the recommended evaluation and treatment approach for distant metastases in thyroid cancer?

Management of Distant Metastases in Thyroid Cancer

For differentiated thyroid cancer (DTC) with distant metastases, initiate radioactive iodine (RAI) therapy at 100-200 mCi (3.7-7.4 GBq) after TSH stimulation as first-line treatment; if disease becomes RAI-refractory or progressive, lenvatinib is the preferred first-line systemic therapy over sorafenib based on superior progression-free survival benefit. 1

Initial Evaluation and Risk Assessment

For DTC with suspected or confirmed distant metastases:

• Obtain multiple imaging modalities including chest CT, bone scan, and consider FDG-PET for comprehensive metastatic surveillance 1
• Measure high-sensitivity thyroglobulin (Tg) levels (<0.2 ng/ml assays) with or without TSH stimulation 1
• Assess RAI avidity through post-therapy whole body scans after initial RAI administration 1
• Maintain TSH suppression to <0.1 mIU/L with levothyroxine in all patients with structural disease unless contraindicated 1

For medullary thyroid cancer (MTC) with distant metastases:

• Monitor calcitonin (Ctn) and CEA levels; doubling times predict disease behavior and guide treatment timing 1
• Use multiple imaging modalities for localization 1
• Assess for symptomatic peptide secretion (flushing, diarrhea) requiring management as first treatment goal 1

Treatment Algorithm for DTC Distant Metastases

RAI-Avid Disease

Initial RAI therapy approach:

• Administer 100-200 mCi (3.7-7.4 GBq) of ¹³¹I after TSH stimulation (either rhTSH or levothyroxine withdrawal) 1
• Small pulmonary metastases (not visible on chest X-ray) have the best cure rates with RAI, particularly in younger patients 1
• Continue TSH suppression (<0.1 mIU/L) between RAI treatments 1
• Repeat RAI therapy for persistent avid disease until loss of uptake or progression despite uptake 1

RAI-Refractory Disease

Define RAI-refractory status when:

• Lesions never concentrate RAI (non-avid) 1
• Lesions lose ability to concentrate RAI over time 1
• Disease progresses despite maintained RAI avidity 1

Systemic therapy for progressive RAI-refractory DTC:

• Lenvatinib is the preferred first-line multikinase inhibitor (MKI) with ESMO-MCBS score of 3, providing 14.7 months median PFS gain (HR 0.21) 1
• Sorafenib is an alternative first-line option with ESMO-MCBS score of 2, providing 5.0 months median PFS gain (HR 0.59) 1
• For BRAF V600E-positive malignancies, use dabrafenib 150 mg twice daily plus trametinib 2 mg once daily 1
• Discuss expected benefits and toxicity risks with patients before initiating MKI therapy 1

Important caveat: Neither lenvatinib nor sorafenib has demonstrated overall survival benefit in trials; initiate only for symptomatic disease, high tumor burden, or documented RECIST v1.1 progression 1

Site-Specific Locoregional Therapies

Pulmonary metastases:

• Metastasectomy may be considered for oligometastatic disease in patients with good performance status 1
• Radiofrequency ablation (RFA) is an option for solitary lesions or those causing symptoms due to volume/location 1

Bone metastases:

• Use bone resorption inhibitors (bisphosphonates or denosumab) alone or combined with locoregional treatments 1
• External beam radiotherapy (EBRT) combined with RAI for symptomatic lesions, though prognosis remains poor 1, 2
• Surgical intervention for spinal compression or impending pathological fractures in long bones 3
• Limited evidence supports RFA or cryotherapy for bone lesions 1

Brain metastases:

• Surgical resection and/or EBRT are the only therapeutic options (RAI ineffective) 1, 2
• Consider stereotactic radiotherapy or whole-brain radiotherapy to improve prognosis and quality of life 3

Single symptomatic or progressive lesions:

• Eligible for palliative surgery, EBRT, or percutaneous therapies regardless of site 1

Treatment Algorithm for MTC Distant Metastases

First-line systemic therapy for progressive metastatic MTC:

• Cabozantinib (Level I, Grade A evidence) is preferred, offering significant PFS and OS advantages in RET M918T or RAS-mutant MTCs 1
• Vandetanib (Level I, Grade A evidence; ESMO-MCBS score 2) is an alternative first-line option 1
• Selective RET inhibitors (selpercatinib or pralsetinib) for RET-mutant MTC; FDA-approved for patients ≥12 years requiring systemic therapy 1

Treatment timing considerations:

• Systemic MKIs have not demonstrated OS improvement in MTC, so timing of initiation lacks evidence-based guidance 1
• Initiate active treatment for: symptoms, lesions near vital structures, high tumor burden, or RECIST v1.1-defined progression 1
• Indolent disease may be carefully monitored without immediate systemic therapy 1

Limited role for chemotherapy or radionuclide therapy:

• Little evidence supports chemotherapy or radionuclide therapy in MTC 1
• Consider only when MKIs are contraindicated 1

Monitoring and Surveillance

For patients with stable metastatic disease:

• Asymptomatic, stable, RAI-resistant metastases may be carefully monitored for progression without immediate intervention 4
• FDG-PET uptake and serum Tg/TgAb trends predict disease progression and outcomes 1
• Organ-specific imaging: pulmonary CT for lung metastases, MRI/CT/bone scan for bone metastases, brain MRI/CT for CNS involvement 4

Response assessment categories:

• Excellent response: undetectable Tg with negative imaging (14/83 patients with distant metastases achieved this; none recurred) 5
• Structural disease persists in 67% of patients with distant metastases after median 62-month follow-up 5

Critical Pitfalls to Avoid

• Do not delay RAI therapy in RAI-avid distant metastases; this remains the most effective systemic treatment for iodine-concentrating disease 1
• Do not initiate MKI therapy prematurely in asymptomatic, stable disease given lack of OS benefit and significant toxicity 1
• Do not use conventional chemotherapy for DTC; enroll patients in clinical trials of targeted therapies instead 2
• Do not perform incomplete "debulking" surgery for anaplastic thyroid cancer with metastases; it does not affect prognosis 1
• Do not overlook multidisciplinary input for complex metastatic cases involving surgeons, endocrinologists, nuclear medicine, medical oncology, radiation oncology, and palliative care 1